Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

被引：0
作者：
Yifeng Xie
Peiling Su
Yifan Sun
Hongsheng Zhang
Rong Zhao
Liang Li
Lanfen Meng
机构：
[1] The Third Affiliated Hospital of Guangxi University of Chinese medicine,Department of Nephrology
[2] The Third Affiliated Hospital of Guangxi University of Chinese medicine,Department of Clinical Laboratory
[3] The Third Affiliated Hospital of Guangxi University of Chinese medicine,Department of Orthopaedics
来源：
BMC Nephrology | / 18卷
关键词：
Paricalcitol; Vitamin D receptor activator; Secondary hyperparathyroidism (SHPT); Hemodialysis; Peritoneal dialysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 133 条
[31]  
Zhang W(2011)Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease Kidney Int 79 1370-1378
[32]  
Zhang X(2012)Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol Nephrol Dial Transplant 27 2263-2269
[33]  
Li X(2007)Meta-analysis: Vitamin D compounds in chronic kidney disease Ann Intern Med 147 840-853
[34]  
Chen J(2011)What should a guideline panel do when evidence is inconclusive? The case of treatments for CKD-mineral and bone disorder (CKD-MBD) Am J Kidney Dis 58 872-875
[35]  
Li X-H(2011)Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis JAMA 305 1119-1127
[36]  
Feng L(undefined)undefined undefined undefined undefined-undefined
[37]  
Yang Z-H(undefined)undefined undefined undefined undefined-undefined
[38]  
Liao Y-H(undefined)undefined undefined undefined undefined-undefined
[39]  
Moher D(undefined)undefined undefined undefined undefined-undefined
[40]  
Liberati A(undefined)undefined undefined undefined undefined-undefined
12345678910